返回 Agenda
Session 7, Tracks B, C: Key Considerations for Successful Risk Minimization
Session Chair(s)
Marilyne Chamoun, MSc
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau
Health Canada, Canada
Myriam Salem, MSc
Good Pharmacovigilance Practices National Coordinator
Health Canada, Canada
The success of a risk minimization measure or program relies on successful design and implementation of the measures and having good strategies in place to evaluate its effectiveness and overall impact. In this session, we will look more closely at the impact that risk minimization measures can have on stakeholders and discuss design considerations and strategies to ensure successful integration into the target healthcare system.
Learning Objective : - Discuss important considerations for the design and implementation of risk minimization measures that are fit-for-purpose and adaptable to the local healthcare system
- Explain the importance of assessing the effectiveness and impact of risk minimization measure on stakeholders
- Identify data sources and innovative research methods that can generate information on different aspects of risk minimization measure implementation and impact
Speaker(s)
Methodological Considerations for Successful Risk Minimization
Yola Moride, PhD, FISPE
YolaRx Consultants and Rutgers University, Canada
President
Key Considerations for Successful Risk Minimisation
Sarah Frise, PhD, MS
AstraZeneca, Canada
Global Head Safety Epidemiology and Risk Management
Speaker
Marilyne Chamoun, MSc
Health Canada, Canada
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau